Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

November 21, 2024 | John Murphy | Leave a Comment

Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

Authors: Bruce K. Patterson, 1 , * Edgar B. Francisco, 1 Ram Yogendra, 2 et. al., Front Immunol. 2021; 12: 746021.Published online 2022 Jan 10. doi: 10.3389/fimmu.2021. 746021PMCID: PMC8784688PMID: 35082777 Abstract The recent COVID-19 pandemic is a treatment challenge in the acute…[...]

November 20, 2024 | John Murphy | Leave a Comment

The Link Between Blood Types And Risks of COVID-19, Cancer, And Other Diseases

Authored by Ellen Wan via The Epoch Times Blood types play a crucial role not only in ensuring safe blood transfusions but also in influencing various health risks. Numerous studies suggest…[...]

November 20, 2024 | John Murphy | Leave a Comment

Study Finds 1 in 4 Americans May Have Long COVID

By Lynn C. Allison, A newly released study finds that one in four Americans may suffer from long COVID, a much higher rate than typically cited. Scientists at Mass General Brigham…[...]

November 20, 2024 | John Murphy | Leave a Comment

Mesenteric Panniculitis and COVID-19: A Rare Association

Authors: Israa A Alyousef,1Zainab A Alsaileek,1Manar A Alabdulsalam,1et. al. Cureus. 2022 Jan; 14(1): e21314. . doi: 10.7759/cureus.21314 PMCID: PMC8849467PMID: 35186573 Abstract Coronavirus disease 2019 (COVID-19) typically involves the respiratory system, but gastrointestinal involvement is common.…[...]

November 19, 2024 | John Murphy | Leave a Comment

Role of 2-Deoxy-D-Glucose in Enhancing the Efficacy of Standard of Care for Moderate to Severe COVID-19: A Comparative Analysis of Clinical Outcomes

Triven Sagar Sandepogu • Chennakesavulu Dara • Saranya Mallamgunta •, et. al. DOI: 10.7759/cureus.73993 Abstract Objective This study aimed to evaluate the role of 2-Deoxy-D-Glucose (2-DG) in moderate to severe Coronavirus Disease 2019 (COVID-19) cases. Methodology…[...]

November 19, 2024 | John Murphy | Leave a Comment

Threatening Eye Condition Rare After COVID Infection

Authors: Steven Reinberg, US News & World Report As doctors learn more about COVID-19 infection, they are finding that in rare cases, it appears tied to a disturbing eye condition.…[...]

November 18, 2024 | John Murphy | Leave a Comment

New-onset chronic musculoskeletal pain following COVID-19 infection fulfil the Fibromyalgia clinical syndrome criteria

Omar Khoja, Matthew Mulvey, Sarah Astill, et. al. doi: https://doi.org/10.1101/2024.07.10.24310234 Abstract Background: New-onset chronic musculoskeletal (MSK) pain (> 3 months duration) is one of the commonest persistent symptoms of Post-COVID syndrome (PCS). There is emerging evidence that…[...]

November 17, 2024 | John Murphy | Leave a Comment

Kansas City Attorney General’s legal report on the case against Pfizer

BY CARL HENEGHAN, 2024 PHARMA, VACCINES We’ve extracted the main points from the Kansas City Attorney General’s legal report on the case against Pfizer that we first mentioned in Due Process—all quotes are…[...]

November 16, 2024 | John Murphy | Leave a Comment

Study Reveals Why COVID-19 Vaccine Antibodies Wane Rapidly

Authored by Marina Zhang via The Epoch Times Research led by scientists at Emory University in Atlanta found that while tetanus and influenza vaccines prompt the body to produce long-lived…[...]

November 16, 2024 | John Murphy | Leave a Comment

Cutting Edge: Hyperinflammatory Monocytes Expressing CD56 Abound in Severe COVID-19 Patients

Stefania Campana; Claudia De Pasquale; Giacomo Sidoti Migliore;, et. al. J Immunol (2022) 209 (4): 655–659. https://doi.org/10.4049/jimmunol.2200021 Abstract Proinflammatory monocytes play a preponderant role in the development of a cytokine storm…[...]